Back to Search
THOMAS STINCHCOMBE, MD
MD
Medical Oncology Physician
NPI: 1265510416IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
9800708(NC)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
9800708(NC)
Education
UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE
Class of 1995
Research & Publications (20)
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
PMID 19652624·J Thorac Oncol·2009
4-observational
Current treatments for advanced stage non-small cell lung cancer.
PMID 19349493·Proc Am Thorac Soc·2009
6-review
Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy.
PMID 19179904·J Thorac Oncol·2009
6-review
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
PMID 18978566·J Thorac Oncol·2008
3-trial
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
PMID 18978563·J Thorac Oncol·2008
3-trial
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
PMID 18784157·Oncologist·2008
8-other
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.
PMID 18449006·J Thorac Oncol·2008
3-trial
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
PMID 18317067·J Thorac Oncol·2008
4-observational
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
PMID 18303435·J Thorac Oncol·2008
3-trial
Considerations for second-line therapy of non-small cell lung cancer.
PMID 18263772·Oncologist·2008
6-review
Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer.
PMID 17805059·J Thorac Oncol·2007
8-other
Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
PMID 17716129·Nanomedicine (Lond)·2007
6-review
Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer.
PMID 17443003·J Clin Oncol·2007
5-case
The role of induction therapy for resectable non-small cell lung cancer.
PMID 17335293·Drugs·2007
6-review
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
PMID 17285317·Cancer Chemother Pharmacol·2007
3-trial
Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan.
PMID 17050879·J Clin Oncol·2006
5-case
Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status.
PMID 16764751·Clin Lung Cancer·2006
6-review
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
PMID 16638621·Lung Cancer·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 101 MANNING DR
CHAPEL HILL, NC 27599 - Phone
- (919) 966-4996
Quick Facts
- NPI
- 1265510416
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 31
- Publications
- 20
Are you this provider?
Claim Your Profile